{
    "nct_id": "NCT03003520",
    "official_title": "A Phase 2, Open-label, Multicenter Study to Evaluate the Safety and Clinical Activity of Durvalumab in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) or With Lenalidomide Plus R-CHOP (R2-CHOP) in Subjects With Previously Untreated, High-Risk Diffuse Large B-Cell Lymphoma",
    "inclusion_criteria": "1. CD20+Diffuse Large B-Cell Lymphoma.\n2. Ann Arbor stage 3 or 4 or stage 2 with bulky disease\n3. High or high-intermediate disease risk.\n4. No prior anti-lymphoma treatment.\n5. Subject is willing and able to undergo biopsy.\n6. Investigator considers R-CHOP immunochemotherapy appropriate.\n7. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.\n8. Adequate hematology laboratory results (absolute neutrophil count ≥ 1.5 * 10^9/L, platelet count ≥ 75 * 10^9/L, hemoglobin ≥ 10.0 g/dL).\n9. Adequate biochemistry laboratory results (aspartate aminotransferase (AST/SGOT) and alanine aminotransferase (ALT/SGPT) ≤ 3.0 * upper limit of normal; bilirubin ≤ 2.0 mg/dL; creatinine clearance of ≥ 40 mL/min).\n10. Bi-dimensionally measurable disease (> 2.0 cm).\n11. Subject is using effective contraception.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "1. Diagnosis of lymphoma other than Diffuse Large B-Cell Lymphoma.\n2. Composite lymphoma or transformed lymphoma.\n3. Primary or secondary Central Nervous System involvement by lymphoma.\n4. Seropositive or active viral infection with hepatitis B virus, human immunodeficiency virus or hepatitis C virus.\n5. History of other malignancies, unless disease-free for ≥ 5 years.\n6. Left ventricular ejection fraction < 50%.\n7. Peripheral neuropathy ≥ Grade 2.\n8. Prior use of lenalidomide, or monoclonal antibodies against CTLA-4, PD-1, or PD-L1.\n9. High risk of developing thromboembolic events, who are unwilling to take venous thromboembolism prophylaxis.\n10. Active or prior documented autoimmune or inflammatory disorders within the past 3 years.\n11. Current or prior use of immunosuppressive medication within 28 days before start of treatment.",
    "miscellaneous_criteria": ""
}